
GRAIL Investor Relations Material
Latest events

Q4 2024
GRAIL
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from GRAIL
Access all reports
GRAIL, Inc. is a biotechnology company specializing in the development of advanced technologies for early cancer detection. The company's primary product is the Galleri test, a multi-cancer early detection test designed to screen for a wide range of cancers, particularly those without current recommended screenings. In addition to Galleri, GRAIL is also working on diagnostic aids and minimal residual disease tests to assist in the detection and monitoring of cancer. The company is headquartered in Menlo Park, California, and its shares are listed on the Nasdaq.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
GRAL
Country
🇺🇸 United States